CONTEXT: African Americans disproportionately experience greater smoking attributable morbidity and mortality. Few clinical trials for smoking cessation in African Americans have been conducted, despite a different profile of both smoking and quitting patterns. OBJECTIVE: To compare a sustained-release form of bupropion hydrochloride (bupropion SR) with placebo for smoking cessation among African Americans. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted from February 11, 1999, to December 8, 2000, of 600 African American adults treated at a community-based health care center. Volunteers, who smoked 10 or more cigarettes per day were recruited by targeted media and health care professionals. INTERVENTION: Participants were randomly assigned to receive 150 mg of bupropion SR (n = 300) or placebo (n = 300) twice daily for 7 weeks. Brief motivational counseling was provided in-person at baseline, quit day, weeks 1 and 3, end of treatment (week 6), and by telephone at day 3 and weeks 5 and 7. MAIN OUTCOME MEASURES: Biochemically confirmed 7-day point prevalence abstinence at weeks 6 and 26 following quit day. RESULTS: Using intention-to-treat procedures, confirmed abstinence rates at the end of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0% in the placebo group (17.0 percentage point difference; 95% confidence interval, 9.7-24.4; P<.001). At 26 weeks the quit rates were 21.0% in the treatment and 13.7% in the placebo groups (7.3 percentage point difference; 95% confidence interval, 1.0-13.7; P =.02). Those taking bupropion SR experienced a greater mean reduction in depression symptoms at week 6 (2.96 [9.45] vs 1.13 [8.84]) than those taking placebo, and after controlling for continuous abstinence, those taking bupropion SR also gained less weight than those taking placebo. CONCLUSIONS:Bupropion SR was effective for smoking cessation among African Americans and may be useful in reducing the health disparities associated with smoking.
RCT Entities:
CONTEXT: African Americans disproportionately experience greater smoking attributable morbidity and mortality. Few clinical trials for smoking cessation in African Americans have been conducted, despite a different profile of both smoking and quitting patterns. OBJECTIVE: To compare a sustained-release form of bupropion hydrochloride (bupropion SR) with placebo for smoking cessation among African Americans. DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted from February 11, 1999, to December 8, 2000, of 600 African American adults treated at a community-based health care center. Volunteers, who smoked 10 or more cigarettes per day were recruited by targeted media and health care professionals. INTERVENTION: Participants were randomly assigned to receive 150 mg of bupropion SR (n = 300) or placebo (n = 300) twice daily for 7 weeks. Brief motivational counseling was provided in-person at baseline, quit day, weeks 1 and 3, end of treatment (week 6), and by telephone at day 3 and weeks 5 and 7. MAIN OUTCOME MEASURES: Biochemically confirmed 7-day point prevalence abstinence at weeks 6 and 26 following quit day. RESULTS: Using intention-to-treat procedures, confirmed abstinence rates at the end of 7 weeks of treatment were 36.0% in the bupropion SR group and 19.0% in the placebo group (17.0 percentage point difference; 95% confidence interval, 9.7-24.4; P<.001). At 26 weeks the quit rates were 21.0% in the treatment and 13.7% in the placebo groups (7.3 percentage point difference; 95% confidence interval, 1.0-13.7; P =.02). Those taking bupropion SR experienced a greater mean reduction in depression symptoms at week 6 (2.96 [9.45] vs 1.13 [8.84]) than those taking placebo, and after controlling for continuous abstinence, those taking bupropion SR also gained less weight than those taking placebo. CONCLUSIONS:Bupropion SR was effective for smoking cessation among African Americans and may be useful in reducing the health disparities associated with smoking.
Authors: Rebecca L Clausius; Ron Krebill; Matthew S Mayo; Carrie Bronars; Laura Martin; Jasjit S Ahluwalia; Lisa Sanderson Cox Journal: Nicotine Tob Res Date: 2012-01-12 Impact factor: 4.244
Authors: Taneisha S Buchanan; Carla J Berg; Lisa Sanderson Cox; Niaman Nazir; Neal L Benowitz; Lisa Yu; Olivia Yturralde; Peyton Jacob; Won S Choi; Jasjit S Ahluwalia; Nicole L Nollen Journal: Nicotine Tob Res Date: 2012-02-24 Impact factor: 4.244
Authors: Lisa Sanderson Cox; Nicole L Nollen; Matthew S Mayo; Won S Choi; Babalola Faseru; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia Journal: J Natl Cancer Inst Date: 2012-01-25 Impact factor: 13.506
Authors: Lisa M Fucito; Amy E Latimer; Shannon Carlin-Menter; Peter Salovey; K Michael Cummings; Robert W Makuch; Benjamin A Toll Journal: Drug Alcohol Depend Date: 2010-10-30 Impact factor: 4.492
Authors: Richard A Brown; Raymond Niaura; Elizabeth E Lloyd-Richardson; David R Strong; Christopher W Kahler; Ana M Abrantes; David Abrams; Ivan W Miller Journal: Nicotine Tob Res Date: 2007-07 Impact factor: 4.244
Authors: Babalola Faseru; Nicole L Nollen; Matthew S Mayo; Ron Krebill; Won S Choi; Neal L Benowitz; Rachel F Tyndale; Kolawole S Okuyemi; Jasjit S Ahluwalia; Lisa Sanderson Cox Journal: Addict Behav Date: 2012-11-29 Impact factor: 3.913
Authors: Man Ki Ho; Babalola Faseru; Won S Choi; Nicole L Nollen; Matthew S Mayo; Janet L Thomas; Kolawole S Okuyemi; Jasjit S Ahluwalia; Neal L Benowitz; Rachel F Tyndale Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-12 Impact factor: 4.254